These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8900336)

  • 1. Lipid management: current diet and drug treatment options.
    Stone NJ
    Am J Med; 1996 Oct; 101(4A):4A40S-48S; discussion 48S-49S. PubMed ID: 8900336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia and coronary artery disease.
    Kuo PT
    Clin Cardiol; 1994 Oct; 17(10):519-27. PubMed ID: 8001298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
    McKenney JM
    Pharmacotherapy; 1993; 13(4):340-52. PubMed ID: 8361860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
    Ito MK
    Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of dyslipidemia in adults.
    Ahmed SM; Clasen ME; Donnelly JE
    Am Fam Physician; 1998 May; 57(9):2192-2204, 2207-8. PubMed ID: 9606309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of pharmacologic therapy for the treatment of dyslipidemia.
    Lipsy RJ
    J Manag Care Pharm; 2003; 9(1 Suppl):9-12. PubMed ID: 14613353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
    Andrews TC; Whitney EJ; Green G; Kalenian R; Personius BE
    Am J Cardiol; 1997 Oct; 80(7):831-5. PubMed ID: 9381993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for combined dyslipidemia.
    Xydakis AM; Ballantyne CM
    Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.